{"id":"NCT04124614","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","briefTitle":"Brexpiprazole as Combination Therapy With Sertraline in Treatment of Adults With PTSD","officialTitle":"A Phase 3, Multicenter, Randomized, Double-blind Trial of Brexpiprazole as Combination Therapy With Sertraline in the Treatment of Adults With Post-traumatic Stress Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-10-17","primaryCompletion":"2023-07-19","completion":"2023-08-08","firstPosted":"2019-10-11","resultsPosted":"2025-06-13","lastUpdate":"2025-06-13"},"enrollment":450,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Post Traumatic Stress Disorder"],"interventions":[{"type":"DRUG","name":"Brexpiprazole","otherNames":["Rexulti"]},{"type":"DRUG","name":"Sertraline","otherNames":["Zoloft"]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo","type":"OTHER"},{"label":"Brexpiprazole + Sertraline","type":"EXPERIMENTAL"},{"label":"Sertraline + Placebo","type":"EXPERIMENTAL"}],"summary":"This will be a 12-week, multicenter, randomized, double-blind trial evaluating the efficacy, safety, and tolerability of brexpiprazole + sertraline combination treatment in adult participants with Post-Traumatic Stress Disorder.","primaryOutcome":{"measure":"Change From Baseline in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) Total Score","timeFrame":"Baseline (Week 1), Week 10","effectByArm":[{"arm":"Brexpiprazole + Sertraline","deltaMin":-19.19,"sd":1.17},{"arm":"Sertraline + Placebo","deltaMin":-13.61,"sd":1.24}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0007"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":4},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["39693081"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":205},"commonTop":["Nausea","Headache","Diarrhoea","Fatigue","Tremor"]}}